Evidence map›Paper›PMID 32989561›Full record

ReviewArchives of osteoporosis2020

FRAX: re-adjust or re-think.

Yasser El Miedany

Abstract readReview
In one paragraph

Review in Archives of osteoporosis, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed, 5 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 5 syntheses or guidelines pooled it.

  1. Pooled it
  2. Updated practice guideline for dual-energy X-ray absorptiometry (DXA).European journal of nuclear medicine and molecular imaging · 2025
    Guideline
  3. Pooled it
  4. Guideline
  5. Pooled it
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Observational
  14. Article
  15. Article
  16. Article
  17. Article
  18. Performance of FRAX in older adults with frailty: the Framingham Heart Study.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2024
    Article
  19. Autoantibodies Serum Level and 10-Year Risk of Fractures Evaluated by FRAXOpen access rheumatology : research and reviews · 2024
    Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Yasser El MiedanyKing's College London, London, England. yasser.el-miedany@nhs.net.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Since its development in 2008, FRAX has booked its place in the standard day to day management of osteoporosis. The FRAX tool has been appreciated for its simplicity and applicability for use in primary care, but criticised for the same reason, as it does not take into account exposure response. To address some of these limitations, relatively simple arithmetic procedures have been proposed to be applied to the conventional FRAX estimates of hip and major fracture probabilities aiming at adjustment of the probability assessment. However, as the list of these adjustments got longer, this has reflected on its implementation in the standard practice and gave FRAX a patchy look. Consequently, raises the need to re-think of the current FRAX and whether a second generation of the tool is required to address the perceived limitations of the original FRAX. This article will discuss both point of views of re-adjustment and re-thinking.

Indexed as

Hip FracturesOsteoporosisOsteoporotic FracturesAdultBone DensityFemaleHumansPrimary Health CareRisk AssessmentAdjustmentArtificial intelligenceBMDClinical risk factorsFracture probabilityFRAXIntervention thresholdsOsteoporosisRisk assessmentScreening

Identifiers

PMID32989561
PMCPMC7522068

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.